2017
KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
Juárez M, Egoavil C, Rodríguez-Soler M, Hernández-Illán E, Guarinos C, García-Martínez A, Alenda C, Giner-Calabuig M, Murcia O, Mangas C, Payá A, Aparicio JR, Ruiz FA, Martínez J, Casellas JA, Soto JL, Zapater P, Jover R. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLOS ONE 2017, 12: e0184937. PMID: 28953955, PMCID: PMC5617162, DOI: 10.1371/journal.pone.0184937.Peer-Reviewed Original ResearchConceptsAdvanced adenomasKRAS mutationsColonic polypsAdvanced neoplasiaAdvanced polypsMetachronous advanced neoplasiaHigh-grade dysplasiaSomatic KRAS mutationsBRAF somatic mutationsMetachronous neoplasiaSurveillance colonoscopyPathologic characteristicsSplenic flexureGrade dysplasiaVillous componentUnivariate analysisSerrated polypsRisk featuresSomatic BRAFMultivariate analysisAdenomasAbstractTextPolypsPatientsNeoplasia
2016
Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis
Dulai PS, Singh S, Marquez E, Khera R, Prokop LJ, Limburg PJ, Gupta S, Murad MH. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. The BMJ 2016, 355: i6188. PMID: 27919915, PMCID: PMC5137632, DOI: 10.1136/bmj.i6188.Peer-Reviewed Original ResearchConceptsLow-dose aspirinNon-aspirin NSAIDsMetachronous neoplasiaDose aspirinColorectal neoplasiaColorectal cancerChemoprevention agentsSystematic reviewCandidate agentCandidate chemoprevention agentsMetachronous colorectal cancerHigh-dose aspirinPrimary efficacy outcomeSerious adverse eventsEfficacy of agentsQuality of evidenceWeb of ScienceEfficacy outcomesAdverse eventsFavorable riskSafety profileBenefit profileClinical trialsGRADE criteriaSafety outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply